Silence Therapeutics appoints Jørgen Wittendorff

Silence Therapeutics appoints Jørgen Wittendorff as Head of Manufacturing

05 August, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Joining the Company's senior management team, he will be responsible for the process development and manufacturing of siRNA therapeutic products for clinical trials and, ultimately, commercial use.

Mr. Wittendorff brings with him over 25 years of experience in the development of pharmaceutical products, having previously held various senior positions within the industry. Most recently, he was Senior Director, CMC Manufacturing and Product Supply at Ablynx, later acquired by Sanofi for EUR 3.9 billion, where he oversaw complex CMC manufacturing processes and regulatory filing of biologics, amongst other key functions. Mr Wittendorff's successful track record is further proven by senior positions at Ferring Pharmaceuticals and Novo Nordisk.

Mr. Wittendorff obtained a master's degree in Pharmacy from the University of Copenhagen.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:"Jørgen's extensive experience in complex manufacturing from Ablynx will be a significant contribution to Silence and it is a pleasure to welcome someone of his calibre to the senior management team. In his new role, Jørgen will be able to critically contribute to the manufacturing efforts to progress Silence's three significant sets of assets in gene silencing siRNA: SLN124, for the treatment of iron overload disorders, SL360, for the treatment of cardiovascular disease, and SL500 with partner Mallinckrodt Pharmaceuticals, for the treatment of complement-mediated disorders."

Jørgen Wittendorff, newly appointed Head of Manufacturing of Silence Therapeutics, commented: "Silence has an impressive portfolio of assets in the siRNA field and it is exciting to be involved in the development of products which have the potential to positively impact the lives of patients with serious diseases. I look forward to working with the rest of the senior management team at this exciting point in the company's journey."

Enquiries:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/